Document Detail

Respiratory support in meconium aspiration syndrome: a practical guide.
Jump to Full Text
MedLine Citation:
PMID:  22518190     Owner:  NLM     Status:  In-Data-Review    
Meconium aspiration syndrome (MAS) is a complex respiratory disease of the term and near-term neonate. Inhalation of meconium causes airway obstruction, atelectasis, epithelial injury, surfactant inhibition, and pulmonary hypertension, the chief clinical manifestations of which are hypoxaemia and poor lung compliance. Supplemental oxygen is the mainstay of therapy for MAS, with around one-third of infants requiring intubation and mechanical ventilation. For those ventilated, high ventilator pressures, as well as a relatively long inspiratory time and slow ventilator rate, may be necessary to achieve adequate oxygenation. High-frequency ventilation may offer a benefit in infants with refractory hypoxaemia and/or gas trapping. Inhaled nitric oxide is effective in those with pulmonary hypertension, and other adjunctive therapies, including surfactant administration and lung lavage, should be considered in selected cases. With judicious use of available modes of ventilation and adjunctive therapies, infants with even the most severe MAS can usually be supported through the disease, with an acceptably low risk of short- and long-term morbidities.
Peter A Dargaville
Publication Detail:
Type:  Journal Article     Date:  2012-02-23
Journal Detail:
Title:  International journal of pediatrics     Volume:  2012     ISSN:  1687-9759     ISO Abbreviation:  Int J Pediatr     Publication Date:  2012  
Date Detail:
Created Date:  2012-04-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101517077     Medline TA:  Int J Pediatr     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  965159     Citation Subset:  -    
Department of Paediatrics, Royal Hobart Hospital and University of Tasmania, Hobart, TAS 7000, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Int J Pediatr
Journal ID (publisher-id): IJPED
ISSN: 1687-9740
ISSN: 1687-9759
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2012 Peter A. Dargaville.
Received Day: 15 Month: 9 Year: 2011
Accepted Day: 19 Month: 12 Year: 2011
Print publication date: Year: 2012
Electronic publication date: Day: 23 Month: 2 Year: 2012
Volume: 2012E-location ID: 965159
ID: 3299298
PubMed Id: 22518190
DOI: 10.1155/2012/965159

Respiratory Support in Meconium Aspiration Syndrome: A Practical Guide
Peter A. Dargaville1, 2I2*
1Department of Paediatrics, Royal Hobart Hospital and University of Tasmania, Hobart, TAS 7000, Australia
2Neonatal Respiratory Group, Menzies Research Institute, Hobart, TAS 7000, Australia
Correspondence: *Peter A. Dargaville:
[other] Academic Editor: Mei-Jy Jeng

1. Introduction

Meconium aspiration syndrome (MAS) is complex respiratory disease of the term and near-term neonate that continues to place a considerable burden on neonatal intensive care resources worldwide. The condition has features that make it stand alone amongst neonatal respiratory diseases—the unique combination of airflow obstruction, atelectasis, and lung inflammation, the high risk of coexistent pulmonary hypertension, and the fact of these occurring in a term infant with a relatively mature lung structurally and biochemically. For all these reasons, management of MAS, and in particular the ventilatory management of MAS, has been a difficult challenge for neonatologists down the years. This paper focuses on application of mechanical respiratory support in MAS, as well as the role of adjunctive respiratory therapies. For the purpose of the paper, MAS is defined as respiratory distress occurring soon after delivery in a meconium-stained infant, which is not otherwise explicable and is associated with a typical radiographic appearance [1].

2. Pathophysiology and Effects on Gas Exchange and Lung Compliance

Lung dysfunction in MAS is a variable interplay of several pathophysiological disturbances, chief amongst which are airway obstruction, atelectasis, and pulmonary hypertension. Meconium, the viscid pigmented secretion of the fetal intestinal tract [2], is a noxious substance when inhaled, producing one of the worst forms of aspiration pneumonitis encountered in humans. Meconium has many adverse biophysical properties, including high tenacity (stickiness) [3], very high surface tension (215 mN/m) [3], and potent inhibition of surfactant function [46]. It is also directly toxic to the pulmonary epithelium [7], causing a haemorrhagic alveolitis with high concentrations of protein and albumin in the alveolar space [8]. Meconium contains substances that are chemotactic to neutrophils [9] and activate complement [10] and may in addition be vasoactive [11]. These adverse properties of meconium are reflected in the pathophysiological disturbances known to occur in MAS [12].

Once inhaled, migration of meconium down the tracheobronchial tree initially causes obstruction of airways of progressively smaller diameter [1315]. At least in experimental MAS, there can be a considerable component of “ball-valve” obstruction, with high resistance to airflow in expiration, resulting in gas trapping distal to the obstruction [14]. If global in distribution, high functional residual capacity (FRC) may result, although only in a small proportion of infants with MAS is there measurably high FRC [16, 17], and even then only transiently [17]. For most infants with MAS, the predominant consequence of airway obstruction with meconium is downstream atelectasis [18]. The patchy nature of the airway obstruction results in a juxtaposition of atelectatic and normally aerated lung units, which has been clearly shown histologically [18], and is reflected in the patchy opacification typically noted on chest X-ray in MAS (Figure 1) [19].

After migration to the level of the alveoli, meconium induces a combination of haemorrhagic alveolitis and surfactant inhibition. Meconium is toxic to the alveolar epithelium [7, 20], causing disruption of the alveolocapillary barrier and an exudative oedema not unlike that seen in acute respiratory distress syndrome. The underlying lung interstitium shows inflammatory cell infiltrate [13, 15], and there is a cytokine release in part related to complement activation [10, 21, 22]. Moreover, meconium causes a potent dose-dependent inhibition of surfactant function [46] and, along with fibrinogen and haemoglobin in the exudate [23, 24], impairs the capacity of endogenous surfactant to reduce surface tension. Stability of alveoli at end-expiration is thus compromised [25], as is the capacity to clear oedema fluid from the airspaces [26]. The resultant microatelectasis causes variable degrees of ventilation-perfusion mismatch or, worse still, intrapulmonary shunt.

The most prominent and consistent physiological effects resulting from meconium injury are hypoxaemia and decreased lung compliance. Some degree of hypoxaemia is universal in symptomatic MAS, contributed to by many of the above-mentioned noxious effects of meconium. Disturbances of oxygenation in MAS may relate to atelectasis, overdistension, pulmonary hypertension, or a combination of these. A challenging aspect of the management of MAS is to discern which mechanism of hypoxaemia is the predominant one in any given infant at any given time. Particularly where there is prominent airway obstruction or pronounced atelectasis, hypoxaemia may be accompanied by respiratory acidosis with CO2 retention related to hypoventilation.

Lung or respiratory system compliance is usually significantly impaired in infants requiring ventilation with MAS [17, 22, 2730]. Experimental studies have indicated that decreased compliance may be related to hyperinflation secondary to “ball-valve” airway obstruction [14], and the combination of poor compliance and high FRC has been demonstrated in some cases of MAS [17]. For most infants with MAS, in whom FRC is normal or low [17], poor compliance relates to global or regional atelectasis. Application of mechanical ventilation further complicates the picture, potentially leading to overdistension of relatively unaffected lung regions which, due to their relatively long time constant, may empty incompletely during the ventilator expiratory cycle, especially at fast ventilator rates [31]. Respiratory resistance has also been noted to be increased in some studies, but variations in the technique of measurement make interpretation of these results difficult.

MAS is frequently accompanied by persistent pulmonary hypertension of the newborn (PPHN) [32], with many factors contributing to its development, including low pO2 and pH, coexistent intrauterine asphyxia, and possibly vasoactive substances in the meconium itself [33].

3. Stepwise Approach to Respiratory Support
3.1. Oxygen Therapy

Supplemental oxygen administration is the mainstay of treatment for MAS and in many less severe cases is the only therapy required [34]. Some ventilated infants with MAS receive high inspired oxygen concentration for long periods, with few apparent adverse effects. Therapeutic considerations in cases of persistently high oxygen requirement are outlined in Table 1.

As with the preterm infant, moment-by-moment adjustment of oxygen concentration (or flow) in infants with MAS is guided oxygen saturation measured by pulse oximetry (SpO2). Given the high incidence of right-to-left ductal shunting related to pulmonary hypertension, a pre-ductal SpO2 is preferable, with the target range for SpO2 being higher than that for the preterm infant, usually between 94 and 98%. In ventilated infants, oxygen therapy can also be monitored by blood gas sampling from an intra-arterial line, preferably in a preductal position in the right radial artery. Suggested target pO2 range is 60–100 mm Hg (preductal). Where there is considerable PPHN, titration of FiO2 using postductal pO2 values is not advisable.

Approach to hypoxaemia in MAS.

3.2. Continuous Positive Airway Pressure

Of all infants requiring mechanical respiratory support because of MAS, approximately 10–20% are treated with continuous positive airway pressure (CPAP) alone [3436]. Additionally, up to one-quarter of infants requiring intubation with MAS receive CPAP before and/or after their period of ventilation [36]. CPAP for such infants can be effectively delivered by binasal prongs or a single nasal prong, typically with a CPAP pressure of 5–8 cm H2O. Tolerance of the CPAP device may be limited given the relative maturity of infants with MAS, and on occasions the associated discomfort will exacerbate pulmonary hypertension to the point where intubation becomes necessary.

3.3. Intubation

Approximately one-third of all infants with a diagnosis of MAS require intubation and mechanical ventilation [33, 37]. Indications for intubation of infants with MAS include (a) high oxygen requirement (FiO2 > 0.8), (b) respiratory acidosis, with arterial pH persistently less than 7.25, (c) pulmonary hypertension, and (d) circulatory compromise, with poor systemic blood pressure and perfusion [38]. Except in emergency circumstances, intubation of infants with MAS should be performed with premedication. Significant endotracheal tube leak is a major barrier to effective ventilation in infants with MAS, and in most cases a size 3.5 mm internal diameter endotracheal tube will be required. Once intubated, tolerance of the endotracheal tube will almost certainly require ongoing sedation with infusions of an opiate (e.g., morphine or fentanyl) [39], possibly supplemented with a benzodiazepine. Additionally, continuation of muscle relaxant drugs is often helpful during the stabilisation period after intubation, particularly in infants with coexistent pulmonary hypertension.

3.4. Conventional Mechanical Ventilation

Despite more than four decades of mechanical ventilation for infants with MAS, the ventilatory management of the condition remains largely in the realm of “art” rather than “science”, with very few clinical trials upon which to base definitive recommendations. Physiological principles and published experience do, however, allow some guiding principles to be put forward for conventional ventilation strategy in MAS.

3.4.1. Choosing a Mode of Ventilation

Ventilation mode and the value of patient-triggering have been incompletely studied in MAS. Two randomised trials of patient-triggered ventilation have included infants with MAS. One of these found no advantage of synchronised intermittent mandatory ventilation (SIMV) over IMV in 15 infants with MAS [40]. Another study found, in a group of 93 infants >2 kg birth weight (including an unspecified number with MAS), that use of SIMV was associated with a shorter duration of ventilation compared with IMV [41]. Despite the relative paucity of evidence in favour, it seems logical to use a synchronized mode of ventilation in any spontaneously breathing ventilated infant with MAS. Trigger sensitivity should be set somewhat higher than that for a preterm infant and should take into account the possibility of autocycling if there is a tube leak [42]. There have been no clinical trials in patients with MAS comparing SIMV and synchronised intermittent positive pressure ventilation (SIPPV), also known as assist control. Given the propensity for gas trapping in MAS, there is some concern that using SIPPV may lead to high levels of inadvertent positive end-expiratory pressure (PEEP) with resultant hyperinflation. For this reason SIMV may be the most appropriate mode of ventilation in MAS.

3.4.2. Selection of Positive End-Expiratory Pressure

For any newborn respiratory disease, but particularly MAS, application of PEEP must balance the competing interests of overcoming atelectasis whilst avoiding overdistension. Early observations of the effect of PEEP suggested the greatest benefit with PEEP settings between 4 and 7 cm H2O, with higher PEEP settings (8–14 cm H2O) giving minimal oxygenation benefit [43]. No more recent clinical studies exist to guide PEEP selection in MAS. Physiological principles dictate that if atelectasis predominates (Figure 1(b)), increasing PEEP (up to a maximum of 10 cm H2O) should improve oxygenation, whereas for regional or global hyperinflation (Figure 1(c)) a lower PEEP (3-4 cm H2O) may be effective (Table 1) [38]. For infants with severe atelectasis, PEEP settings above 10 cm H2O are likely to increase the risk of pneumothorax [44], and modes of high frequency ventilation are to be preferred if available.

3.4.3. Selection of Inspiratory Time

As with PEEP, setting inspiratory time in MAS must take into account the balance between atelectasis and overdistension. Term infants have generally longer time constants than their preterm counterparts [45] and thus require a longer inspiratory time (around 0.5 sec) to allow near-full equilibration of lung volume change in response to the applied peak pressure. Even longer inspiratory times may be useful for lung recruitment during inspiration if atelectasis is prominent.

3.4.4. Selection of Peak Inspiratory Pressure (or Tidal Volume)

Given the reduced compliance, the peak inspiratory pressure (PIP) required to generate sufficient tidal volume in MAS is often high (30 cm H2O or more). Such pressures may well contribute to a secondary ventilator-induced lung injury in ventilated infants with MAS. Suggested target tidal volume is 5-6 mL/kg. If using a “volume guarantee” mode, the peak pressure limit should be set at or near 30 cm H2O to allow the ventilator to scale up the PIP when needed to reach the tidal volume target. If PIP is persistently higher than 30 cm H2O, high frequency ventilation should be considered, if available.

3.4.5. Selection of Ventilator Rate

Especially if there is gas-trapping and expiratory airflow limitation, optimal conventional ventilation in MAS requires the use of a relatively low ventilator rate (<50) and hence longer expiratory time. This will help to avoid inadvertent PEEP. The resultant minute ventilation must be sufficient to produce adequate CO2 clearance. An acceptable arterial pCO2 range is 40–60 mm Hg and pH 7.3-7.4, which is achievable in most infants even when there is significant parenchymal disease combined with PPHN [46]. Hyperventilation-induced alkalosis, which anecdotally appeared to reduce the need for extracorporeal membrane oxygenation (ECMO) in infants with PPHN [47], is no longer practiced, in part due to the risk of sensorineural hearing loss [48].

3.5. High-Frequency Oscillatory Ventilation

Despite the dearth of clinical trial, evidence suggesting a benefit, high frequency oscillatory ventilation (HFOV) has become an important means of providing respiratory support for infants with severe MAS failing conventional ventilation. Published series from large neonatal databases suggest that 20–30% of all infants requiring intubation and ventilation with MAS are treated with high-frequency ventilation [34, 36, 49], with most of these receiving HFOV rather than high-frequency jet ventilation (HFJV). Indications for transitioning to HFOV include ongoing hypoxaemia and/or high FiO2, and, less commonly, respiratory acidosis. In infants with significant atelectasis, adequate lung recruitment may require the application of a mean airway pressure (PAW) considerably higher than that on conventional ventilation (up to 25 cm H2O in some cases), with a stepwise recruitment manoeuvre likely to be the most effective [50]. Once oxygenation has improved, PAW should then be reduced; most infants with MAS requiring HFOV can be stabilised using a PAW around 16–20 cm H2O, with gradual weaning in the days thereafter [51]. Infants with prominent gas trapping may tolerate the recruitment process poorly, with reductions in oxygenation and systemic blood pressure and the potential for exacerbation of pulmonary hypertension. Recruitment manoeuvres of some form can still be advantageous in this group, with the benefit becoming apparent when the PAW is reduced.

Choice of oscillatory frequency is critically important in MAS, with experimental studies and clinical experience indicating that frequency should not be higher than 10 Hz and preferably should be set at 8 or even 6 Hz. In experimental models of MAS, high oscillatory frequency (15 Hz) is associated with worsening of gas trapping [52]. HFOV can also lend a clinical advantage in infants with significant coexisting PPHN, as the response to inhaled nitric oxide (iNO) is better when delivered on HFOV compared to conventional ventilation [53]. Early reports suggested that up to half of infants with MAS treated with HFOV did not respond adequately and went on to receive ECMO [54, 55]. More recent experience would suggest that only around 5% of infants treated with HFOV and iNO fail to respond and undergo transition to ECMO [36].

3.6. High-Frequency Jet Ventilation

The combination of atelectasis and gas trapping that can occur in MAS may be better managed with HFJV than HFOV (Table 1), with the former technique offering the possibility of ventilation at a lower PAW [56]. A number of laboratory investigations have shown HFJV, either alone or in combination with surfactant therapy, to be beneficial in animal models of MAS [18, 56, 57]. Clinical studies including infants with MAS appear to confirm the benefit of HFJV compared with conventional ventilation, both in terms of improvement in oxygenation, and avoidance of ECMO [58, 59]. Whilst there have been no direct comparisons with HFOV in a clinical setting, we have noted that some infants with intractable hypoxaemia and/or respiratory acidosis do show improvements after transition from HFOV to HFJV using a low-frequency (240–360 bpm) and a low conventional ventilator rate [60].

4. Adjunctive Respiratory Therapies
4.1. Bolus Surfactant Therapy

The pathophysiology of MAS includes inhibition of surfactant in the airspaces, both by meconium and exuded plasma proteins [46, 23]. Preliminary reports of the use of exogenous surfactant given as bolus therapy to ventilated infants with MAS were promising, although it was identified that around 40% of cases did not respond [61]. Four randomised controlled trials of bolus surfactant therapy have been conducted [6265], which when analysed together show a benefit in terms of reduction in need for ECMO but not duration of ventilation or other pulmonary outcomes [66]. In the developed world, bolus surfactant therapy is currently used in 30–50% of ventilated infants with MAS [34, 36]. Bolus surfactant therapy should be used judiciously in MAS, choosing infants with severe disease, and treating early and, if necessary, repeatedly [12].

4.2. Lavage Therapy

Lung lavage using dilute surfactant is an emerging treatment for MAS that offers the potential of interrupting the pathogenesis of the disease by removal of meconium from the airspaces [12]. Laboratory studies and preliminary clinical evaluations have indicated that lavage therapy may improve oxygenation and shorten duration of ventilation in MAS [6769]. A recent randomised controlled trial of large-volume lavage using dilute surfactant in infants with severe MAS noted no effect on duration of respiratory support or other pulmonary outcomes but did find a higher rate of ECMO-free survival in the treated group [70]. Further clinical trials will be necessary to more precisely define the effect on survival.

4.3. Corticosteroid Therapy

Steroid therapy has been investigated in MAS for more than 3 decades, with a number of small clinical trials being conducted, none of which have given a definitive result. One recent trial suggested that dexamethasone therapy could dampen the inflammatory response in MAS [71]. In the absence of further trials, steroid therapy cannot be recommended as routine therapy in MAS.

4.4. Inhaled Nitric Oxide

Large randomised controlled trials have demonstrated the effectiveness of iNO in term infants with pulmonary hypertension, with a reduction in need for ECMO and in the composite outcome of death or requirement for ECMO [72]. Each trial included a large subgroup with MAS; overall more than 640 infants with MAS have been enrolled in iNO trials, although few have reported the outcome for MAS separately. The potential value of delivering iNO during HFOV has been highlighted in one trial, in which the proportion of nonresponders was lowest when the two therapies were combined [53]. Currently around 20–30% of all ventilated infants with MAS receive iNO [34, 36], and around 40–60% show a sustained response [46, 53].

The approach to an infant with MAS and coexistent PPHN should initially focus on optimising the ventilatory management and in particular overcoming atelectasis whilst avoiding hyperinflation, both of which are associated with an increase in pulmonary vascular resistance. The severity of PPHN should be assessed clinically and by echocardiogram if available. If moderate-severe PPHN persists after appropriate ventilatory manoeuvres and the pO2 remains at less than 80–100 mm Hg in FiO2 1.0 [53, 73], iNO should commence at a dose of 10–20 ppm. Higher doses do not appear to result in better oxygenation [74].

4.5. Extracorporeal Membrane Oxygenation

Infants with severe MAS have been treated with ECMO since 1976, and MAS has been the leading diagnosis amongst neonates referred for this therapy [75]. ECMO is now available to infants with MAS in selected centres in 33 countries worldwide [76], albeit at a high cost (at least 2.5 times the daily cost of standard intensive care) [77]. With the advent of newer therapies, the number of infants with MAS treated with ECMO has decreased [78], but survival with ECMO treatment for MAS has remained high (around 95%) [75]. The usual indication for commencing ECMO is intractable hypoxaemia despite optimisation of the patient's condition with available therapies (including high-frequency ventilation and iNO) and bolus surfactant therapy). Degree of hypoxaemia in this setting has generally been quantified using oxygenation index (OI), where OI = PAW × FiO2 × 100/PaO2. An OI persistently above 40 despite aggressive standard management has been, and remains, an indication for treatment with ECMO where available [79]. Followup of newborn infants treated with ECMO because of parenchymal lung disease (excluding diaphragmatic hernia) suggests a low rate of severe disability at one year (1.7% in the UK ECMO trial) [80], with the risk of any disability being 17% [80].

4.6. Liquid Ventilation

To the author's knowledge, there is as yet no report of clinical use of perfluorocarbon in MAS. Both total liquid ventilation with perfluorocarbon and perfluorocarbon-assisted gas exchange have been investigated in animal models of MAS [8183]. Both techniques have shown short-term advantages over conventional ventilatory management, with better oxygenation and lung compliance [81, 83]. Total liquid ventilation appears to be the most lung protective, resulting in much reduced meconium-associated histological damage compared with conventional ventilation or PAGE [81]. The complications of perfluorocarbon instillation noted in human subjects, including pneumothorax, impaired carbon dioxide clearance, and delayed excretion, may be significant barriers to the clinical use of liquid ventilation in ventilated infants with MAS.

Perfluorocarbon has also been considered as a possible vehicle for lung lavage in MAS, especially given the favourable biophysical properties including high oxygen carrying capacity and low surface tension. Despite these potential advantages, use of neither pure [84] nor emulsified [69] perfluorocarbon as a lavage fluid has shown any major advantage over dilute surfactant. Even when followed by perfluorocarbon-assisted gas exchange, the benefits of perfluorocarbon lavage appear minimal [83]. This may be due to the relatively high density of perfluorocarbon and/or the relative immiscibility of meconium with perfluorochemicals.

5. Outcome of Ventilation in MAS
5.1. Duration of Ventilation and Oxygen Therapy

Considering all intubated infants with MAS, median duration of ventilation is 3 days (mean 4.8 days) [36]. Infants with more severe disease, requiring at least one of high-frequency ventilation, iNO or bolus surfactant, are ventilated for a median of 5 days [36]. Median duration of oxygen therapy and length of hospital stay currently stand at 7 and 17 days, respectively [36].

5.2. Mortality

Refinements in intensive care and respiratory support have contributed to a significant decrease in mortality related to MAS, with population-based studies now suggesting a mortality of 1-2 per 100,000 live births [36, 85, 86]. The case-fatality rate in ventilated infants with MAS varies widely in published series (0–37%) [37] and is influenced by availability of alternative means of ventilation, adjunctive therapies including nitric oxide, and ECMO. Approximately one-quarter to one-third of all deaths in ventilated infants with a diagnosis of MAS are directly attributable to the pulmonary disease, with the remainder in large part caused by hypoxic-ischaemic encephalopathy [34, 36, 86].

5.3. Short-Term Morbidities

Pneumothorax occurs in around 10% of all ventilated infants with MAS [36, 87], and the presence of this complication potentiates lung atelectasis and PPHN and increases the risk of mortality [36, 88]. Other air leak syndromes, including pneumomediastinum and pulmonary interstitial emphysema, are seen occasionally. Pulmonary haemorrhage (or, more correctly, haemorrhagic pulmonary oedema) occurs in a small proportion of infants with MAS and can occasionally cause severe destabilisation and hypoxaemia [89].

5.4. Long-Term Morbidities

Respiratory compromise after hospital discharge is common in infants who were ventilated with MAS. Up to half of infants will be symptomatic with wheezing and coughing in the first year of life [90]. Older children may exhibit evidence of airway obstruction, hyperinflation, and airway hyperreactivity, but appear to have normal aerobic capacity [91]. Neurological sequelae following MAS are well recognized [37], and a diagnosis of MAS in the neonatal period confers a considerable risk of cerebral palsy (5–10%) [92, 93] and global developmental delay (15%) [92].

6. Conclusion

With judicious use of available modes of ventilation and adjunctive therapies, infants with even the most severe MAS can usually be supported through the disease, with an acceptable burden of short-and long-term morbidity.

Conflict of Interests

No conflict of interests is declared.

1. Wiswell TE,Henley MA. Intratracheal suctioning, systemic infection, and the meconium aspiration syndromePediatricsYear: 19928922032061734384
2. Harries JT. Meconium in health and diseaseBritish Medical BulletinYear: 19783417578342053
3. Rubin BK,Tomkiewicz RP,Patrinos ME,Easa D. The surface and transport properties of meconium and reconstituted meconium solutionsPediatric ResearchYear: 19964068348388947959
4. Moses D,Holm BA,Spitale P,Liu MY,Enhorning G. Inhibition of pulmonary surfactant function by meconiumAmerican Journal of Obstetrics and GynecologyYear: 199116424774811992687
5. Sun B,Curstedt T,Robertson B. Surfactant inhibition in experimental meconium aspirationActa PaediatricaYear: 19938221821898477165
6. Herting E,Rauprich P,Stichtenoth G,Walter G,Johansson J,Robertson B. Resistance of different surfactant preparations to inactivation by meconiumPediatric ResearchYear: 2001501444911420417
7. Oelberg DG,Downey SA,Flynn MM. Bile salt-induced intracellular Ca++ accumulation in type II pneumocytesLungYear: 199016862973082126319
8. Dargaville PA,South M,McDougall PN. Surfactant and surfactant inhibitors in meconium aspiration syndromeThe Journal of PediatricsYear: 2001138111311511148523
9. de Beaufort AJ,Pelikan DMV,Elferink JGR,Berger HM. Effect of interleukin 8 in meconium on in-vitro neutrophil chemotaxis The LancetYear: 19983529122102105
10. Castellheim A,Lindenskov PHH,Pharo A,Aamodt G,Saugstad OD,Mollnes TE. Meconium aspiration syndrome induces complement-associated systemic inflammatory response in newborn pigletsScandinavian Journal of ImmunologyYear: 200561321722515787738
11. Holcberg G,Huleihel M,Katz M,et al. Vasoconstrictive activity of meconium stained amniotic fluid in the human placental vasculatureEuropean Journal of Obstetrics & Gynecology and Reproductive BiologyYear: 199987214715010597964
12. Dargaville PA,Mills JF. Surfactant therapy for meconium aspiration syndrome: current statusDrugsYear: 200565182569259116392874
13. Tyler DC,Murphy J,Cheney FW. Mechanical and chemical damage to lung tissue caused by meconium aspirationPediatricsYear: 1978624454459714576
14. Tran N,Lowe C,Sivieri EM,Shaffer TH. Sequential effects of acute meconium obstruction on pulmonary functionPediatric ResearchYear: 198014134387360519
15. Davey AM,Becker JD,Davis JM. Meconium aspiration syndrome: physiological and inflammatory changes in a newborn piglet modelPediatric PulmonologyYear: 19931621011088367215
16. Dimitriou G,Greenough A. Measurement of lung volume and optimal oxygenation during high frequency oscillationArchives of Disease in ChildhoodYear: 1995723, supplementF180F1837796234
17. Yeh TF,Lilien LD,Barathi A,Pildes RS. Lung volume, dynamic lung compliance, and blood gases during the first 3 days of postnatal life in infants with meconium aspiration syndromeCritical Care MedicineYear: 19821095885927105768
18. Wiswell TE,Peabody SS,Davis JM,Slayter MV,Bent RC,Merritt TA. Surfactant therapy and high-frequency jet ventilation in the management of a piglet model of the meconium aspiration syndromePediatric ResearchYear: 19943644945007816525
19. Yeh TF,Harris V,Srinivasan G,Lilien L,Pyati S,Pildes RS. Roentgenographic findings in infants with meconium aspiration syndromeThe Journal of the American Medical AssociationYear: 197924216063
20. Higgins ST,Wu AM,Sen N,Spitzer AR,Chander A. Meconium increases surfactant secretion in isolated rat alveolar type II cellsPediatric ResearchYear: 19963934434478929864
21. Jones CA,Cayabyab RG,Kwong KYC,et al. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newbornsPediatric ResearchYear: 19963969669758725256
22. Cayabyab RG,Kwong K,Jones C,Minoo P,Durand M. Lung inflammation and pulmonary function in infants with meconium aspiration syndromePediatric PulmonologyYear: 2007421089890517722052
23. Fuchimukai T,Fujiwara T,Takahashi A,Enhorning G. Artificial pulmonary surfactant inhibited by proteinsJournal of Applied PhysiologyYear: 19876224294373558203
24. Holm BA,Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activityJournal of Applied PhysiologyYear: 1987634143414423693177
25. Possmayer F. Polin RA,Fox WW,Abman SHPhysicochemical aspects of pulmonary surfactantFetal and Neonatal PhysiologyYear: 2004Philadelphia, Pa, USAW.B. Saunders10141034
26. Carlton DP,Cho SC,Davis P,Lont M,Bland RD. Surfactant treatment at birth reduces lung vascular injury and edema in preterm lambsPediatric ResearchYear: 19953732652707784133
27. Brudno DS,Boedy RF,Kanto WP Jr.. Compliance, alveolar-arterial oxygen difference, and oxygenation index changes in patients managed with extracorporeal membrane oxygenationPediatric PulmonologyYear: 19909119232388774
28. Beeram MR,Dhanireddy R. Effects of saline instillation during tracheal suction on lung mechanics in newborn infantsJournal of PerinatologyYear: 19921221201231522428
29. Kugelman A,Saiki K,Platzker AC,Garg M. Measurement of lung volumes and pulmonary mechanics during weaning of newborn infants with intractable respiratory failure from extracorporeal membrane oxygenationPediatric PulmonologyYear: 19952031451518545165
30. Szymankiewicz M,Gadzinowski J,Kowalska K. Pulmonary function after surfactant lung lavage followed by surfactant administration in infants with severe meconium aspiration syndromeJournal of Maternal-Fetal and Neonatal MedicineYear: 200416212513015512724
31. Ramsden CA,Reynolds EO. Ventilator settings for newborn infantsArchives of Disease in ChildhoodYear: 19876255295383606193
32. Abu-Osba YK. Treatment of persistent pulmonary hypertension of the newborn: updateArchives of Disease in ChildhoodYear: 199166174771996900
33. Wiswell TE,Bent RC. Meconium staining and the meconium aspiration syndrome: unresolved issuesPediatric Clinics of North AmericaYear: 19934059559818414717
34. Singh BS,Clark RH,Powers RJ,Spitzer AR. Meconium aspiration syndrome remains a significant problem in the NICU: outcomes and treatment patterns in term neonates admitted for intensive care during a ten-year periodJournal of PerinatologyYear: 200929749750319158800
35. Wiswell TE,Gannon CM,Jacob J,et al. Delivery room management of the apparently vigorous meconium-stained neonate: results of the multicenter, international collaborative trialPediatricsYear: 200010511710617696
36. Dargaville PA,Copnell B. The epidemiology of meconium aspiration syndrome: incidence, risk factors, therapies, and outcomePediatricsYear: 200611751712172116651329
37. Cleary GM,Wiswell TE. Meconium-stained amniotic fluid and the meconium aspiration syndrome: an updatePediatric Clinics of North AmericaYear: 19984535115299653434
38. Goldsmith JP. Continuous positive airway pressure and conventional mechanical ventilation in the treatment of meconium aspiration syndromeJournal of PerinatologyYear: 200828supplement 3S49S5519057611
39. Aranda JV,Carlo W,Hummel P,Thomas R,Lehr VT,Anand KJS. Analgesia and sedation during mechanical ventilation in neonatesClinical TherapeuticsYear: 200527687789916117990
40. Chen JY,Ling UP,Chen JH. Comparison of synchronized and conventional intermittent mandatory ventilation in neonatesActa Paediatrica JaponicaYear: 19973955785839363656
41. Bernstein G,Mannino FL,Heldt GP,et al. Randomized multicenter trial comparing synchronized and conventional intermittent mandatory ventilation in neonatesThe Journal of PediatricsYear: 199612844534638618177
42. Bernstein G,Knodel E,Heldt GP. Airway leak size in neonates and autocycling of three flow-triggered ventilatorsCritical Care MedicineYear: 19952310173917447587241
43. Fox WW,Berman LS,Downes JJ Jr.,Peckham GJ. The therapeutic application of end expiratory pressure in the meconium aspiration syndromePediatricsYear: 19755622142171099523
44. Probyn ME,Hooper SB,Dargaville PA,et al. Positive end expiratory pressure during resuscitation of premature lambs rapidly improves blood gases without adversely affecting arterial pressurePediatric ResearchYear: 200456219820415181198
45. Wood BR. Goldsmith JP,Karotkin EH,et al.Physiologic principlesAssisted Ventilation of the NeonateYear: 2003Philadelphia, Pa, USASaunders1540
46. Gupta A,Rastogi S,Sahni R,et al. Inhaled nitric oxide and gentle ventilation in the treatment of pulmonary hypertension of the newborn—a single-center, 5-year experienceJournal of PerinatologyYear: 200222643544112168118
47. Walsh-Sukys MC,Tyson JE,Wright LL,et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomesPediatricsYear: 20001051142010617698
48. Hendricks-Munoz KD,Walton JP. Hearing loss in infants with persistent fetal circulationPediatricsYear: 19888156506562451802
49. Tingay DG,Mills JF,Morley CJ,Pellicano A,Dargaville PA. Trends in use and outcome of newborn infants treated with high frequency ventilation in Australia and New Zealand, 1996–2003Journal of Paediatrics and Child HealthYear: 200743316016617316190
50. Pellicano A,Tingay DG,Mills JF,Fasulakis S,Morley CJ,Dargaville PA. Comparison of four methods of lung volume recruitment during high frequency oscillatory ventilationIntensive Care MedicineYear: 200935111990199819756507
51. Dargaville PA,Mills JF,Copnell B,Loughnan PM,McDougall PN,Morley CJ. Therapeutic lung lavage in meconium aspiration syndrome: a preliminary reportJournal of Paediatrics and Child HealthYear: 2007437-853954517635682
52. Hachey WE,Eyal FG,Curtet-Eyal NL,Kellum FE. High-frequency oscillatory ventilation versus conventional ventilation in a piglet model of early meconium aspirationCritical Care MedicineYear: 19982635565619504586
53. Kinsella JP,Truog WE,Walsh WF,et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newbornThe Journal of PediatricsYear: 1997131155629255192
54. Carter JM,Gerstmann DR,Clark RH,et al. High-frequency oscillatory ventilation and extracorporeal membrane oxygenation for the treatment of acute neonatal respiratory failurePediatricsYear: 19908521591642296503
55. Paranka MS,Clark RH,Yoder BA,Null DM Jr.. Predictors of failure of high-frequency oscillatory ventilation in term infants with severe respiratory failurePediatricsYear: 19959534004047862480
56. Keszler M,Molina B,Butterfield AB,Subramanian KNS. Combined high-frequency jet ventilation in a meconium aspiration modelCritical Care MedicineYear: 198614134383940752
57. Wiswell TE,Foster NH,Slayter MV,Hachey WE. Management of a piglet model of the meconium aspiration syndrome with high-frequency or conventional ventilationAmerican Journal of Diseases of ChildrenYear: 199214611128712931415063
58. Davis JM,Richter SE,Kendig JW,Notter RH. High-frequency jet ventilation and surfactant treatment of newborns with severe respiratory failurePediatric PulmonologyYear: 19921321081121495854
59. Engle WA,Yoder MC,Andreoli SP,Darragh RK,Langefeld CD,Hui SL. Controlled prospective randomized comparison of high-frequency jet ventilation and conventional ventilation in neonates with respiratory failure and persistent pulmonary hypertensionJournal of PerinatologyYear: 1997171399069056
60. Kamlin O,Loughnan P,Dargaville P,Mills J,McDougall P. Outcomes from the first seven years of rescue therapy with high frequency jet ventilation in critically ill newborns in a tertiary referral centreIn: Proceedings of the 19th Annual Conference of High Frequency Ventilation in Infants2002Snowbird, Utah, USA
61. Halliday HL,Speer CP,Robertson B. Treatment of severe meconium aspiration syndrome with porcine surfactant. Collaborative Surfactant Study GroupEuropean Journal of PediatricsYear: 199615512104710518956943
62. Findlay RD,Taeusch HW,Walther FJ. Surfactant replacement therapy for meconium aspiration syndromePediatricsYear: 199697148528545223
63. Lotze A,Mitchell BR,Bulas DI,et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study GroupThe Journal of PediatricsYear: 1998132140479469998
64. Chinese Collaborative Study Group for Neonatal Respiratory DiseasesTreatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trialActa PaediatricaYear: 200594789690216188812
65. Maturana A,Torres-Pereyra J,Salinas R,Astudillo P,Moya FR,TheChile Surf Group. A randomized trial of natural surfactant for moderate to severe meconium aspiration syndromePediatric ResearchYear: 200557, article 1545A
66. El Shahed AI,Dargaville P,Ohlsson A,Soll RF. Surfactant for meconium aspiration syndrome in full term/near term infantsCochrane Database of Systematic ReviewsYear: 20073 Article ID CD002054..
67. Cochrane CG,Revak SD,Merritt TA,et al. Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndromePediatric ResearchYear: 19984457057159803452
68. Wiswell TE,Knight GR,Finer NN,et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndromePediatricsYear: 200210961081108712042546
69. Dargaville PA,Mills JF,Headley BM,et al. Therapeutic lung lavage in the piglet model of meconium aspiration syndromeAmerican Journal of Respiratory and Critical Care MedicineYear: 2003168445646312714351
70. Dargaville PA,Copnell B,Mills JF,et al. Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndromeThe Journal of PediatricsYear: 2011158338338920947097
71. Tripathi S,Saili A,Dutta R. Inflammatory markers in meconium induced lung injury in neonates and effect of steroids on their levels: a randomized controlled trialIndian Journal of Medical MicrobiologyYear: 200725210310717582178
72. Finer NN,Barrington KJ. Nitric oxide for respiratory failure in infants born at or near termCochrane Database of Systematic ReviewsYear: 20064 Article ID CD000399..
73. Wessel DL,Adatia I,van Marter LJ,et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newbornPediatricsYear: 19971005, article E7
74. Guthrie SO,Walsh WF,Auten K,Clark RH. Initial dosing of inhaled nitric oxide in infants with hypoxic respiratory failureJournal of PerinatologyYear: 200424529029415042110
75. Short BL. Extracorporeal membrane oxygenation: use in meconium aspiration syndromeJournal of PerinatologyYear: 200828supplement 3S79S8319057615
76. ELSO Registry. ECLS Centers by Category, December 2011,
77. Petrou S,Edwards L. Cost effectiveness analysis of neonatal extracorporeal membrane oxygenation based on four year results from the UK Collaborative ECMO TrialArchives of Disease in ChildhoodYear: 2004893, supplementF263F26815102733
78. Fliman PJ,deRegnier RAO,Kinsella JP,Reynolds M,Rankin LL,Steinhorn RH. Neonatal extracorporeal life support: impact of new therapies on survivalThe Journal of PediatricsYear: 2006148559559916737868
79. UK Collaborative ECMO Trial GroupUK collaborative randomised trial of neonatal extracorporeal membrane oxygenationThe LancetYear: 199634890207582
80. Mugford M,Elbourne D,Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infantsCochrane Database of Systematic ReviewsYear: 20083 Article ID CD001340..
81. Foust R,Tran NN,Cox C,et al. Liquid assisted ventilation: an alternative ventilatory strategy for acute meconium aspiration injuryPediatric PulmonologyYear: 19962153163228726157
82. Nakamura T,Matsuzawa S,Sugiura M,Tamura M. A randomised control study of partial liquid ventilation after airway lavage with exogenous surfactant in a meconium aspiration syndrome animal modelArchives of Disease in ChildhoodYear: 2000822, supplementF160F16210685992
83. Jeng MJ,Soong WJ,Lee YS,et al. Effects of therapeutic bronchoalveolar lavage and partial liquid ventilation on meconium-aspirated newborn pigletsCritical Care MedicineYear: 20063441099110516484898
84. Schlösser RL,Veldman A,Fischer D,Funk B,Brand J,von Loewenich V. Comparison of effects of perflubron and surfactant lung lavage on pulmonary gas exchange in a piglet model of meconium aspirationBiology of the NeonateYear: 200281212613111844883
85. Sriram S,Wall SN,Khoshnood B,Singh JK,Hsieh HL,Lee KS. Racial disparity in meconium-stained amniotic fluid and meconium aspiration syndrome in the United States, 1989–2000Obstetrics and GynecologyYear: 200310261262126814662213
86. Nolent P,Hallalel F,Chevalier JY,Flamant C,Renolleau S. Meconium aspiration syndrome requiring mechanical ventilation: incidence and respiratory management in France (2000-2001)Archives de PediatrieYear: 200411541742215135423
87. Wiswell TE,Tuggle JM,Turner BS. Meconium aspiration syndrome: have we made a difference?PediatricsYear: 19908557157212330231
88. Lin HC,Su BH,Lin TW,Peng CT,Tsai CH. Risk factors of mortality in meconium aspiration syndrome: review of 314 casesActa Paediatrica TaiwanicaYear: 2004451303415264703
89. Berger TM,Allred EN,van Marter LJ. Antecedents of clinically significant pulmonary hemorrhage among newborn infantsJournal of PerinatologyYear: 200020529530010920787
90. Yuksel B,Greenough A,Gamsu HR. Neonatal meconium aspiration syndrome and respiratory morbidity during infancyPediatric PulmonologyYear: 19931663583618134158
91. Swaminathan S,Quinn J,Stabile MW,Bader D,Platzker CG,Keens TG. Long-term pulmonary sequelae of meconium aspiration syndromeThe Journal of PediatricsYear: 198911433563612921679
92. Beligere N,Rao R. Neurodevelopmental outcome of infants with meconium aspiration syndrome: report of a study and literature reviewJournal of PerinatologyYear: 200828supplement 3S93S10119057618
93. Walstab JE,Bell RJ,Reddihough DS,Brennecke SP,Bessell CK,Beischer NA. Factors identified during the neonatal period associated with risk of cerebral palsyAustralian and New Zealand Journal of Obstetrics and GynaecologyYear: 200444434234615282008

Article Categories:
  • Review Article

Previous Document:  Postmortem cerebrospinal fluid pleocytosis: a marker of inflammation or postmortem artifact?
Next Document:  Leptin in anorexia and cachexia syndrome.